{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:07:02Z","timestamp":1778857622645,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020M2D9A2092373"],"award-info":[{"award-number":["NRF-2020M2D9A2092373"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI23C1573"],"award-info":[{"award-number":["HI23C1573"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Hippocampal injury from WBRT contributes to neurocognitive decline in brain malignancy patients. HA-WBRT may mitigate this by reducing hippocampal radiation exposure, but its feasibility in PCNSL remains unassessed regarding hippocampal involvement and failure rates. This study evaluates hippocampal involvement at diagnosis and after treatment in PCNSL patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>We conducted a retrospective analysis of 278 immunocompetent PCNSL patients diagnosed between 2000 and 2021. Following high-dose methotrexate-based induction chemotherapy, patients either received consolidation therapy, including RT, cytarabine alone, or autologous stem cell transplantation or underwent observation. Hippocampus was outlined on T1 MRI images and expanded by a 5\u00a0mm margin to create the hippocampal avoidance region (HAR). Hippocampal failure was defined as recurrence or progression at HAR. The median follow-up was 38.7\u00a0months (range 3.1\u2013239.4\u00a0months).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 278 patients diagnosed with PCNSL, 39.9% presented initial lesions at HAR. After induction therapy, 212 evaluable patients received consolidation treatments or observation. Intracranial failures occurred in 47.6% (n\u2009=\u2009101), with 66.3% (n\u2009=\u200967) occurring outside the HAR and 33.7% (n\u2009=\u200934) inside the HAR. Unifocal disease (HR 0.61, 95% CI 0.39\u20130.96, p\u2009=\u20090.025) was associated with a lower risk of hippocampal failures, while initial HAR involvement significantly increased the risk (HR 2.26, 95% CI 1.18\u20134.47, p\u2009=\u20090.018). Patients with unifocal disease outside the HAR had the lowest 3-year hippocampal failure rate (6.2%). RT that included the hippocampus did not significantly affect hippocampal failure rates in patients without initial HAR lesions (p\u2009=\u20090.282), with three-year rates of 9.2 vs. 14.6% for other treatments. However, among patients with initial HAR involvement, RT including the hippocampus significantly reduced hippocampal failure rates compared to other approaches (p\u2009=\u20090.002). Hippocampal failure rates were comparable, with conventional WBRT at 14.6% and HA-WBRT at 19% in patients without initial HAR lesions (p\u2009=\u20090.734).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The routine application of the HA-WBRT strategy is not supported due to the high risk of hippocampal failures in general and requires further investigation to establish its feasibility and safety in well-defined subgroups. Our results suggest that the HA-WBRT strategy could be evaluated for select PCNSL patients with unifocal lesions or those located outside the HAR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11060-025-04965-7","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T06:28:27Z","timestamp":1739946507000},"page":"95-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Distribution and failure patterns of primary central nervous system lymphoma related to the hippocampus: implications for hippocampal avoidance irradiation"],"prefix":"10.1007","volume":"173","author":[{"given":"Hyejo","family":"Ryu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul-Kee","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hye","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Kyung","family":"Won","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bum-Sup","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"4965_CR1","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1016\/S1470-2045(18)30356-5","volume":"19","author":"M van der Meulen","year":"2018","unstructured":"van der Meulen M, Dirven L, Habets EJJ, van den Bent MJ, Taphoorn MJB, Bromberg JEC (2018) Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review. Lancet Oncol 19:e407\u2013e418. https:\/\/doi.org\/10.1016\/S1470-2045(18)30356-5","journal-title":"Lancet Oncol"},{"key":"4965_CR2","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","volume":"18","author":"LE Abrey","year":"2000","unstructured":"Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:3144\u20133150. https:\/\/doi.org\/10.1200\/JCO.2000.18.17.3144","journal-title":"J Clin Oncol"},{"key":"4965_CR3","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.esmoop.2021.100213","volume":"6","author":"T Calimeri","year":"2021","unstructured":"Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJM (2021) How we treat primary central nervous system lymphoma. ESMO Open 6:100213. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100213","journal-title":"ESMO Open"},{"key":"4965_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.expneurol.2004.05.005","volume":"188","author":"R Rola","year":"2004","unstructured":"Rola R, Raber J, Rizk A, Otsuka S, VandenBerg SR, Morhardt DR, Fike JR (2004) Radiation-induced impairment of hippocampal neurogenesis is associated with cognitive deficits in young mice. Exp Neurol 188:316\u2013330. https:\/\/doi.org\/10.1016\/j.expneurol.2004.05.005","journal-title":"Exp Neurol"},{"key":"4965_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijrobp.2023.04.030","volume":"117","author":"V Gondi","year":"2023","unstructured":"Gondi V, Deshmukh S, Brown PD, Wefel JS, Armstrong TS, Tome WA, Gilbert MR, Konski A, Robinson CG, Bovi JA, Benzinger TLS, Roberge D, Kundapur V, Kaufman I, Shah S, Usuki KY, Baschnagel AM, Mehta MP, Kachnic LA (2023) Sustained preservation of cognition and prevention of patient-reported symptoms with hippocampal avoidance during whole-brain radiation therapy for brain metastases: final results of nrg oncology CC001. Int J Radiat Oncol Biol Phys 117:571\u2013580. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.030","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4965_CR6","doi-asserted-by":"publisher","first-page":"E31","DOI":"10.1093\/neuros\/nyaa107","volume":"87","author":"C Gui","year":"2020","unstructured":"Gui C, Vannorsdall TD, Kleinberg LR, Assadi R, Moore JA, Hu C, Quinones-Hinojosa A, Redmond KJ (2020) A prospective cohort study of neural progenitor cell-sparing radiation therapy plus temozolomide for newly diagnosed patients with glioblastoma. Neurosurgery 87:E31\u2013E40. https:\/\/doi.org\/10.1093\/neuros\/nyaa107","journal-title":"Neurosurgery"},{"key":"4965_CR7","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1200\/JCO.21.00639","volume":"39","author":"N Rodriguez de Dios","year":"2021","unstructured":"Rodriguez de Dios N, Counago F, Murcia-Mejia M, Rico-Oses M, Calvo-Crespo P, Samper P, Vallejo C, Luna J, Trueba I, Sotoca A, Cigarral C, Farre N, Manero RM, Duran X, Gispert JD, Sanchez-Benavides G, Rognoni T, Torrente M, Capellades J, Jimenez M, Cabada T, Blanco M, Alonso A, Martinez-San Millan J, Escribano J, Gonzalez B, Lopez-Guerra JL (2021) Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): a GICOR-GOECP-SEOR study. J Clin Oncol 39:3118\u20133127. https:\/\/doi.org\/10.1200\/JCO.21.00639","journal-title":"J Clin Oncol"},{"issue":"24","key":"4965_CR8","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","volume":"20","author":"LM DeAngelis","year":"2002","unstructured":"DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ (2002) Radiation therapy oncology group study 93\u201310. combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93\u201310. J Clin Oncol 20(24):4643\u20134648","journal-title":"J Clin Oncol"},{"key":"4965_CR9","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.ijrobp.2010.01.039","volume":"78","author":"V Gondi","year":"2010","unstructured":"Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, Khuntia D, Tome WA (2010) Hippocampal-sparing whole-brain radiotherapy: a \u201chow-to\u201d technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 78:1244\u20131252. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.01.039","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4965_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.radonc.2013.09.009","volume":"109","author":"S Harth","year":"2013","unstructured":"Harth S, Abo-Madyan Y, Zheng L, Siebenlist K, Herskind C, Wenz F, Giordano FA (2013) Estimation of intracranial failure risk following hippocampal-sparing whole brain radiotherapy. Radiother Oncol 109:152\u2013158. https:\/\/doi.org\/10.1016\/j.radonc.2013.09.009","journal-title":"Radiother Oncol"},{"key":"4965_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3857\/roj.2023.00031","volume":"41","author":"H Ryu","year":"2023","unstructured":"Ryu H, Lee JH (2023) Excluding prepontine cistern from whole ventricle radiotherapy target volume in localized germinoma. Radiat Oncol J 41:48\u201357. https:\/\/doi.org\/10.3857\/roj.2023.00031","journal-title":"Radiat Oncol J"},{"key":"4965_CR12","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/cncr.34574","volume":"129","author":"S Baliga","year":"2023","unstructured":"Baliga S, Adams JA, Bajaj BVM, Van Benthuysen L, Daartz J, Gallotto SL, Lewy JR, DeNunzio N, Weyman EA, Lawell MP, Palmer JD, Yeap BY, Ebb DH, Huang MS, Perry AF, MacDonald SM, Jones RM, Tarbell NJ, Yock TI (2023) Patterns of failure in pediatric medulloblastoma and implications for hippocampal sparing. Cancer 129:764\u2013770. https:\/\/doi.org\/10.1002\/cncr.34574","journal-title":"Cancer"},{"key":"4965_CR13","doi-asserted-by":"publisher","first-page":"983","DOI":"10.4143\/crt.2020.1052","volume":"53","author":"JH Lee","year":"2021","unstructured":"Lee JH, Eom KY, Phi JH, Park CK, Kim SK, Cho BK, Kim TM, Heo DS, Hong KT, Choi JY, Kang HJ, Shin HY, Choi SH, Lee ST, Park SH, Wang KC, Kim IH (2021) Long-term outcomes and sequelae analysis of intracranial germinoma: need to reduce the extended-field radiotherapy volume and dose to minimize late sequelae. Cancer Res Treat 53:983\u2013990. https:\/\/doi.org\/10.4143\/crt.2020.1052","journal-title":"Cancer Res Treat"},{"issue":"10","key":"4965_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/JCO.19.02767","volume":"38","author":"PD Brown","year":"2020","unstructured":"Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, Bovi JA, Robinson C, Konski A, Khuntia D, Grosshans D (2020) Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol 38(10):1019\u20131029","journal-title":"J Clin Oncol"},{"key":"4965_CR15","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570\u20134574. https:\/\/doi.org\/10.1200\/JCO.2006.06.6910","journal-title":"J Clin Oncol"},{"key":"4965_CR16","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1001\/archneur.62.10.1595","volume":"62","author":"AM Omuro","year":"2005","unstructured":"Omuro AM, Ben-Porat LS, Panageas KS, Kim AK, Correa DD, Yahalom J, Deangelis LM, Abrey LE (2005) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62:1595\u20131600. https:\/\/doi.org\/10.1001\/archneur.62.10.1595","journal-title":"Arch Neurol"},{"key":"4965_CR17","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, Karimi S, Curry R, Shah G, Abrey LE, DeAngelis LM, Omuro A (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31:3971\u20133979. https:\/\/doi.org\/10.1200\/JCO.2013.50.4910","journal-title":"J Clin Oncol"},{"key":"4965_CR18","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1200\/JCO.2020.38.15_suppl.2501","volume":"38","author":"AMP Omuro","year":"2020","unstructured":"Omuro AMP, DeAngelis LM, Karrison T, Bovi JA, Rosenblum M, Corn BW, Correa D, Wefel JS, Aneja S, Grommes C, Schaff L, Waggoner SE, Lallana EC, Werner-Wasik M, Iwamoto F, Robinson TJ, Donnelly E, Struve T, Won M, Mehta MP (2020) Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). J Clin Oncol 38:2501\u20132501. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.2501","journal-title":"J Clin Oncol"},{"key":"4965_CR19","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1182\/bloodadvances.2022007011","volume":"6","author":"P Lesueur","year":"2022","unstructured":"Lesueur P, Damaj G, Hoang-Xuan K, Roland V, Schmitt A, Chinot O, Fabbro M, Agape P, Molucon-Chabrot C, Chebrek S, Alentorn A, Feuvret L, Delgadillo D, Stefan D, Choquet S, Nichelli L, Mokhtari K, Mathon B, Dureau S, Soussain C, Houillier C (2022) Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood Adv 6:4807\u20134815. https:\/\/doi.org\/10.1182\/bloodadvances.2022007011","journal-title":"Blood Adv"},{"key":"4965_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3857\/roj.2020.00052","volume":"38","author":"TH Lee","year":"2020","unstructured":"Lee TH, Lee JH, Chang JH, Ye SJ, Kim TM, Park CK, Kim IH, Kim BH, Wee CW (2020) Reduced-dose whole-brain radiotherapy with tumor bed boost after upfront high-dose methotrexate for primary central nervous system lymphoma. Radiat Oncol J 38:35\u201343. https:\/\/doi.org\/10.3857\/roj.2020.00052","journal-title":"Radiat Oncol J"},{"key":"4965_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/cncr.11035","volume":"97","author":"Y Shibamoto","year":"2003","unstructured":"Shibamoto Y, Hayabuchi N, Hiratsuka J, Tokumaru S, Shirato H, Sougawa M, Oya N, Uematsu Y, Hiraoka M (2003) Is whole-brain irradiation necessary for primary central nervous system lymphoma? Patterns of recurrence after partial-brain irradiation. Cancer 97:128\u2013133. https:\/\/doi.org\/10.1002\/cncr.11035","journal-title":"Cancer"},{"key":"4965_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11060-015-1786-1","volume":"123","author":"S Hirono","year":"2015","unstructured":"Hirono S, Iwadate Y, Higuchi Y, Serizawa T, Nagano O, Matsutani T, Saeki N (2015) Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma. J Neurooncol 123:237\u2013244. https:\/\/doi.org\/10.1007\/s11060-015-1786-1","journal-title":"J Neurooncol"},{"key":"4965_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2022.12.002","author":"V Manickam Gurusamy","year":"2023","unstructured":"Manickam Gurusamy V, Raveendran Divakar S, Halsnad Chandramouli S, Kunheri B, Hussain Al-Abdulla H, Shaikh G, Chaudary Apsani R, Riyaz Poolakundan M, Caparrotti P, Wafiq Hammoud R, Al-Hammadi N (2023) The role of radiotherapy in newly diagnosed primary CNS lymphoma: a descriptive review and a pragmatic approach to clinical practice. Clin Transl Radiat Oncol. https:\/\/doi.org\/10.1016\/j.ctro.2022.12.002","journal-title":"Clin Transl Radiat Oncol"},{"issue":"11","key":"4965_CR24","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"AJ Ferreri","year":"2017","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Ros\u00e9e P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M (2017) Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the international extranodal lymphoma study group-32 phase 2 trial. Lancet Haematol 4(11):e510\u2013e523","journal-title":"Lancet Haematol"},{"key":"4965_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","volume":"37","author":"C Houillier","year":"2019","unstructured":"Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Molucon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C, Intergroupe G-A, the LOCNfCNSL (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37:823\u2013833. https:\/\/doi.org\/10.1200\/JCO.18.00306","journal-title":"J Clin Oncol"},{"key":"4965_CR26","doi-asserted-by":"publisher","DOI":"10.46439\/HEMATOL.1.004","author":"KW Yeoh","year":"2022","unstructured":"Yeoh KW, Yong FY, Wong CKH, Ong ALK, Swaminathan TI, Chan KP (2022) Primary CNS lymphoma (PCNSL) introducing hippocampal dose-reduction whole brain radiotherapy (HDR-WBRT). J Clin Exp Hematol. https:\/\/doi.org\/10.46439\/HEMATOL.1.004","journal-title":"J Clin Exp Hematol"},{"key":"4965_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13014-023-02251-2","volume":"18","author":"C Mazzarella","year":"2023","unstructured":"Mazzarella C, Chiesa S, Toppi L, Hohaus S, Gaudino S, D\u2019Alo F, Dinapoli N, Davide R, Zinicola T, Bracci S, Martino A, Beghella Bartoli F, Lepre E, Bertolini R, Mariani S, Colosimo C, Frascino V, Mattiucci GC, Gambacorta MA, Valentini V, Balducci M (2023) May we routinely spare hippocampal region in primary central nervous system lymphoma during whole brain radiotherapy? Radiat Oncol 18:161. https:\/\/doi.org\/10.1186\/s13014-023-02251-2","journal-title":"Radiat Oncol"},{"key":"4965_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41586-018-0389-3","volume":"560","author":"JH Lee","year":"2018","unstructured":"Lee JH, Lee JE, Kahng JY, Kim SH, Park JS, Yoon SJ, Um JY, Kim WK, Lee JK, Park J, Kim EH, Lee JH, Lee JH, Chung WS, Ju YS, Park SH, Chang JH, Kang SG, Lee JH (2018) Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature 560:243\u2013247. https:\/\/doi.org\/10.1038\/s41586-018-0389-3","journal-title":"Nature"},{"key":"4965_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.5483\/BMBRep.2018.51.10.233","volume":"51","author":"JH Lee","year":"2018","unstructured":"Lee JH, Lee JH (2018) The origin-of-cell harboring cancer-driving mutations in human glioblastoma. BMB Rep 51:481\u2013483. https:\/\/doi.org\/10.5483\/BMBRep.2018.51.10.233","journal-title":"BMB Rep"},{"key":"4965_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193002","author":"V Llorente","year":"2022","unstructured":"Llorente V, Velarde P, Desco M, Gomez-Gaviro MV (2022) Current understanding of the neural stem cell niches. Cells. https:\/\/doi.org\/10.3390\/cells11193002","journal-title":"Cells"},{"issue":"845\u2013859","key":"4965_CR31","doi-asserted-by":"publisher","first-page":"e819","DOI":"10.1016\/j.cell.2017.07.016","volume":"170","author":"EY Qin","year":"2017","unstructured":"Qin EY, Cooper DD, Abbott KL, Lennon J, Nagaraja S, Mackay A, Jones C, Vogel H, Jackson PK, Monje M (2017) Neural precursor-derived pleiotrophin mediates subventricular zone invasion by glioma. Cell 170(845\u2013859):e819. https:\/\/doi.org\/10.1016\/j.cell.2017.07.016","journal-title":"Cell"},{"key":"4965_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/neuonc\/nou144","volume":"17","author":"N Goffart","year":"2015","unstructured":"Goffart N, Kroonen J, Di Valentin E, Dedobbeleer M, Denne A, Martinive P, Rogister B (2015) Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12\/CXCR4 signaling. Neuro Oncol 17:81\u201394. https:\/\/doi.org\/10.1093\/neuonc\/nou144","journal-title":"Neuro Oncol"},{"key":"4965_CR33","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/JCO.2017.74.5281","volume":"35","author":"AF Herrera","year":"2017","unstructured":"Herrera AF, Armand P (2017) Minimal residual disease assessment in lymphoma: methods and applications. J Clin Oncol 35:3877\u20133887. https:\/\/doi.org\/10.1200\/JCO.2017.74.5281","journal-title":"J Clin Oncol"},{"key":"4965_CR34","doi-asserted-by":"publisher","first-page":"110331","DOI":"10.1016\/j.radonc.2024.110331","volume":"197","author":"S Wiegreffe","year":"2024","unstructured":"Wiegreffe S, Sarria GR, Layer JP, Dejonckheere E, Nour Y, Schmeel FC, Anton Giordano F, Schmeel LC, Popp I, Grosu AL, Gkika E, Stefaan Dejonckheere C (2024) Incidence of hippocampal and perihippocampal brain metastases and impact on hippocampal-avoiding radiotherapy: a systematic review and meta-analysis. Radiother Oncol 197:110331. https:\/\/doi.org\/10.1016\/j.radonc.2024.110331","journal-title":"Radiother Oncol"},{"key":"4965_CR35","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.ijrobp.2024.08.025","volume":"120","author":"FM Hsu","year":"2024","unstructured":"Hsu FM, Yang WC, Lu SL, Lai SF, Yang CC, Lu SH, Chen YF, Kuo SH, Cheng JCH (2024) Neurocognitive outcome of conformal whole brain radiotherapy with bilateral or unilateral hippocampal avoidance plus memantine for brain metastases: a phase II single blind randomized trial. Int J Radiat Oncol Biol Phys 120:S9\u2013S10. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4965_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","volume":"105","author":"U Hegde","year":"2005","unstructured":"Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105:496\u2013502. https:\/\/doi.org\/10.1182\/blood-2004-05-1982","journal-title":"Blood"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04965-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-04965-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-04965-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T08:29:50Z","timestamp":1745915390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-04965-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["4965"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-04965-7","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"3 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study received approval from the Seoul National Hospital\u2019s Institutional Review Board (Number. H-2203-127-1308). The requirement for patient consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}